“Another measure looked at fibrosis, which is measured in five stages. There, 26% of patients showed an improvement of at least one stage in fibrosis while their symptoms didn't progress.”

26% of 950 is 247 patients that experienced non progression of Fibrosis. Or I guess an improvement. It’s a little beyond me to compare that to Leronlimab. Without side by side top line comparisons.

Read More: https://investorshangout.com/post/view?id=651...z7o4iX7xw6